Actively Recruiting
Effect of Early Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury
Led by Tanta University · Updated on 2026-05-14
126
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effect of early treatment with calcitonin on the occurrence and severity of neuropathic pain following spinal cord injury. This study aims to understand how calcitonin might influence different types of pain after spinal cord injury, including musculoskeletal, visceral, and neuropathic pain at various levels. Calcitonin has been used before to manage acute pain in conditions like amputation and vertebral fractures, as well as to prevent complex regional pain syndrome after stroke, making it a candidate for investigation in this setting. Participants will be randomly assigned to receive either 100 IU of calcitonin or a saline placebo through daily subcutaneous injections for two weeks, starting within 48 hours after their spinal cord injury. This is a double-blinded study, meaning neither participants nor researchers know which treatment each participant receives. The treatment period lasts two weeks, and the study includes monitoring for adverse reactions during this time. Throughout the study, participants will be assessed for the intensity and incidence of neuropathic pain at six and twelve months after injury. Researchers will also track the use of medications for neuropathic and musculoskeletal pain, as well as any adverse effects occurring within the first two weeks. This detailed follow-up will help understand the longer-term impact of early calcitonin treatment on pain management after spinal cord injury.
CONDITIONS
Brief Title
Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older
- Diagnosis of spinal cord injury at any level
- Injury in the early stage of trauma
You will not qualify if you...
- Current use of anticonvulsant medications
- Existing neuropathic pain
- Previous allergic reaction to calcitonin
- Kidney, liver, or heart dysfunction
- Neurological disorders
- Brain damage or major trauma to limbs or abdomen
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 weeks
Participants receive either calcitonin or a placebo injection daily for 2 weeks starting within 48 hours after spinal cord injury.
Daily injections for 2 weeks
Duration - Up to 12 months
Participants are monitored for neuropathic pain intensity and incidence, medication consumption, and adverse reactions up to 12 months after injury.
Visits at 2 weeks, 6 months, and 12 months after injury
Trial Site Locations
Total: 1 location
1
Tanta University
Tanta, Gharbia Governorate, Egypt, 31527
Actively Recruiting
Research Team
O
Osama M Rehab, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here